SUPPLEMENTAL MATERIAL

Table S1. Baseline, presentation and in-hospital management characteristics of subjects with 6 month follow up data versus those without 6 month follow up data.

Variable	Statistic/Level	6 month follow up data collected N=2487	Lost to follow up N=594	Overall N=3081
Age	Mean (SD)	60.3 (12.6)	62.3 (12.5)	60.6 (12.8)
	Minimum	23.0	23.0	23.0
	Median (IQR)	60 (51-79)	62 (52-71)	60 (52-69)
Sex	Female (%)	606 (24)	165 (28)	771 (25)
	Male (%)	1881 (76)	429 (72)	2310 (75)
SMuRFs*				
Diabetes (%)		442 (18)	112 (19)	554 (18)
Hypertension (%)		1096 (44)	267 (45)	1363 (44)
Dyslipidaemia (%)		933 (38)	193 (32)	1126 (37)
Current smoker (%)		1008 (41)	235 (40)	1243 (40)
Family history of coronary heart disease (%)		805 (37)	165 (29)	970 (35)
BMI†	Mean (SD)	28.3 (5.3)	28.1 (5.3)	28.2 (5.3)
	Median (IQR)	27.4 (24.8-30.9)	27.5 (24.5-30.9)	27.4 (24.7-30.9)
Previous atrial fibrillation (%)		67 (3)	25 (4)	92 (3)

Variable	Statistic/Level	6 month follow up data collected N=2487	Lost to follow up N=594	Overall N=3081
History of bleeding (%)		24 (1)	3 (1)	27 (1)
Pre-hospital medications				
Statin (%)		398 (16)	91 (15)	489 (16)
Aspirin (%)		309 (12)	63 (11)	372 (12)
P2Y12 Inhibitor (%)		40 (2)	12 (2)	52 (2)
Betablocker (%)		175 (7)	44 (7)	219 (7)
ACE inhibitor (%)§		284 (11)	60 (10)	344 (11)
ARB (%)||		337 (14)	92 (16)	429 (14)
Systolic blood pressure (mmHg)	Mean (SD)	138.1 (21.2)	135.3 (29.7)	137.6 (27.7)
	Median (IQR)	136 (120-155)	135 (115-155)	136 (119-155)
Diastolic blood pressure (mmHg)	Mean (SD)	82.5 (17.2)	81.0 (18.3)	82.2 (17.4)
	Median (IQR)	80 (70-92)	80 (70-93)	80 (70-93)
Heart rate (per min)	Mean (SD)	78.0 (19.3)	80.9 (22.0)	78.6 (19.9)
	Median (IQR)	76 (64-90)	78 (65-94)	76 (65-90)
Killip class	1	2268 (92)	508 (86)	2776 (91)
	2	159 (6)	46 (8)	205 (7)
	3	34 (1)	20 (3)	54 (2)
	4	12 (0)	15 (3)	27 (1)

Variable	Statistic/Level	6 month follow up data collected N=2487	Lost to follow up N=594	Overall N=3081
Cardiac arrest on admission		154 (6)	74 (13)	228 (7)
Abnormal cardiac biomarker		2052 (98)	494 (98)	2546 (98)
Serum creatinine	Mean (SD)	89.1 (29.0)	97.5 (63.3)	90.7 (38.2)
	Median (IQR)	84 (72-100)	88 (73-104)	85 (72-100)
Grace Risk Score (Fox)	Mean (SD)	107.5 (28.1)	116.5 (34.4)	109.2 (29.6)
	Median (IQR)	106 (88-125)	111 (91-136)	107 (89-127)
Left Ventricular function grade				
Normal (%)		508 (36)	118 (36)	626 (36)
Mild impairment (%)		512 (36)	97 (29)	609 (35)
Moderate impairment (%)		329 (23)	89 (27)	418 (24)
Severe impairment (%)		73 (5)	28 (8)	101 (6)
Culprit Lesion Territory				
Left main (%)		4 (1)	1 (2)	5 (1)
Left Anterior Descending (%)		153 (38)	25 (39)	178 (38)
Circumflex Artery (%)		48 (12)	7 (11)	55 (12)
Right Coronary (%)		148 (37)	25 (39)	173 (37)
Unknown (%)		46 (12)	6 (9)	52 (11)
Multi-vessel disease > 50% stenosis (%)		1013 (41)	228 (42)	1241 (41)

Variable	Statistic/Level	6 month follow up data collected N=2487	Lost to follow up N=594	Overall N=3081
In-hospital treatment				
Statin (%)		2318 (93)	484 (82)	2802 (91)
Aspirin (%)		2452 (99)	556 (94)	3008 (98)
P2Y12 Inhibitor (%)		2071 (83)	508 (86)	2579 (84)
ACE Inhbitor (%)§		1819 (73)	355 (60)	2174 (71)
ARB (%)||		251 (10)	71 (12)	322 (10)
Heparin (%)		1938 (78)	462 (78)	2400 (78)
Low molecular weight heparin (%)		830 (33)	166 (28)	996 (32)
Thrombolysis (%)		921 (37)	186 (31)	1107 (36)
Primary PCI in STEMI patients (%)‡§		1113 (45)	277 (47)	1390 (45)
Hospital transfer (%)		1055 (42)	250 (42)	1305 (42)
PCI (%)‡		1724 (69)	399 (67)	2123 (69)
CABG (%)ï		143 (6)	32 (5)	175 (6)
Discharge medications				
Statin (%)		2192 (93)	455 (84)	2647 (92)
Aspirin (%)		2144 (92)	464 (86)	2608 (90)
P2Y12 Inhibitor (%)		1832 (78)	418 (77)	2250 (78)
Betablocker (%)		2003 (85)	403 (74)	2406 (83)

Variable	Statistic/Level	6 month follow up data collected N=2487	Lost to follow up N=594	Overall N=3081
ACE inhibitor (%)§		1675 (71)	303 (56)	1978 (69)
ARB (%)||		205 (9)	60 (11)	265 (9)

*Standard modifiable cardiovascular risk factors (SMuRFs)

†Body mass index (BMI)

‡Coronary heart disease(CHD)

§Angiotensin converting enzyme (ACE)

\|\|Angiotensin II Receptor Antagonist Blocker (ARB)

‡Percutaneous coronary intervention (PCI)

§ST elevation myocardial infarction (STEMI)

Ï Coronary artery bypass graft surgery (CABG)